Indrapr.Medical

When is the next results date for Indrapr.Medical?

No Upcoming Board Meetings

What does Indrapr.Medical do?

Indraprastha Medical Corporation Ltd operates in the hospital industry, providing high-quality healthcare services and is currently establishing a super specialty hospital in New Delhi. As of March 2025, it reported net sales of ₹334 Cr and a net profit of ₹41 Cr, with a market cap of ₹3,956 Cr.

Overview:<BR>Indraprastha Medical Corporation Ltd operates in the hospital industry, focusing on enhancing the quality of life for patients through comprehensive, high-quality hospital services on a cost-effective basis.<BR><BR>History:<BR>The company was incorporated on 16th March, 1988. It has been actively involved in the healthcare sector and is currently setting up a multi-disciplinary super speciality tertiary care referral hospital in New Delhi. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 334 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 41 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: Rs 3,956 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 25.00<BR>- Industry P/E: 54<BR>- Dividend Yield: 1.03%<BR>- Debt Equity: -0.53<BR>- Return on Equity: 30.70%<BR>- Price to Book: 7.63<BR><BR>Contact Details:<BR>Address: Sarita Vihar, Delhi-Mathura Road New Delhi New Delhi : 110076<BR>Tel: 91-11-26925858/26925801<BR>Email: imclshares@apollohospitals.com<BR>Website: http://www.apollohospdelhi.com

Who are in the management team of Indrapr.Medical?

As of March 2023, the management team of Indrapr.Medical includes Chairman Jasmine Shah, Vice Chairman Prathap C Reddy, and a mix of executive and non-executive directors, totaling 16 members, including several independent directors. This diverse board ensures a broad range of expertise and governance for the company.

As of March 2023, the management team of Indrapr.Medical includes the following members:<BR><BR>1. Jasmine Shah - Chairman & Non Executive Director<BR>2. Prathap C Reddy - Vice Chairman & Non Executive<BR>3. Suneeta Reddy - Non Executive Director<BR>4. Sangita Reddy - Non Executive Director<BR>5. Vineeta Rai - Non Executive Director<BR>6. S Regunathan - Independent Non Executive Director<BR>7. Satnam Arora - Independent Non Executive Director<BR>8. Deepak Vaidya - Independent Non Executive Director<BR>9. Arun Rai - Independent Non Executive Director<BR>10. Vinayak Chatterjee - Independent Non Executive Director<BR>11. Madhumita Ganguli - Independent Non Executive Director<BR>12. Menaka Gurusswamy - Independent Non Executive Director<BR>13. Salil Singhal - Independent Non Executive Director<BR>14. Vikram Bhat - Non Executive Director<BR>15. Mahesh Verma - Non Executive Director<BR>16. P Shivakumar - Executive Director & Managing Director<BR><BR>This diverse board includes a mix of executive and non-executive directors, providing a broad range of expertise and governance for the company.

Has Indrapr.Medical declared dividend?

Indraprastha Medical Corporation Ltd has declared a 45% dividend, amounting to 4.5 per share, with an ex-date of September 13, 2024. The company has shown strong total returns over various periods, particularly with a 975.89% total return over the past 5 years.

Indraprastha Medical Corporation Ltd has declared a 45% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 4.5<BR>- Ex-date: 13 Sep 24<BR><BR>Dividend Yield: 1.03%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.98%, with a dividend return of 0%, resulting in a total return of -13.98%.<BR><BR>Over the past year, the price return was 79.61%, the dividend return was 1.76%, leading to a total return of 81.37%.<BR><BR>In the 2-year period, the price return was 378.48%, the dividend return was 8.15%, culminating in a total return of 386.63%.<BR><BR>For the 3-year period, the price return was 635.29%, with a dividend return of 18.55%, resulting in a total return of 653.84%.<BR><BR>In the last 4 years, the price return was 371.31%, the dividend return was 11.77%, leading to a total return of 383.08%.<BR><BR>Over the past 5 years, the price return was 956.99%, with a dividend return of 18.90%, resulting in a total return of 975.89%.<BR><BR>Overall, Indraprastha Medical Corporation Ltd has declared a significant dividend while also showing strong total returns over various periods, particularly in the longer term. The company appears to be performing well, with substantial price appreciation and a reasonable dividend yield.

Who are the peers of the Indrapr.Medical?

Indrapr.Medical's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Artemis Medicare, Dr Agarwal's Eye, Shalby, and GPT Healthcare. Indrapr.Medical has the highest 1-year return at 77.54%, while Shalby has the lowest at -28.88%.

Peers: The peers of Indrapr.Medical are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Artemis Medicare, Dr Agarwal's Eye, Shalby, and GPT Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Narayana Hrudaya, Global Health, and GPT Healthcare, while Good management risk is found at Apollo Hospitals, Indrapr.Medical, and the rest. Average management risk is present at Fortis Health., Dr Agarwal's Eye, Shalby, and KMC Speciality, while Below Average management risk is noted at Artemis Medicare. Excellent growth is seen at Max Healthcare and Apollo Hospitals, while Good growth is found at Indrapr.Medical, Narayana Hrudaya, and the rest. Below Average growth is observed at Artemis Medicare and Shalby, while Average growth is noted at Global Health, Dr Agarwal's Eye, and KMC Speciality. Excellent capital structure is present at Max Healthcare, Global Health, and GPT Healthcare, while Indrapr.Medical has an Excellent capital structure, and Average capital structure is noted at Apollo Hospitals and Artemis Medicare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indrapr.Medical at 77.54%, while the peer with the lowest is Shalby at -28.88%. Indrapr.Medical's 1-year return significantly exceeds that of all its peers. Additionally, Global Health, Artemis Medicare, Dr Agarwal's Eye, Shalby, GPT Healthcare, and KMC Speciality all have negative six-month returns.

Who are the top shareholders of the Indrapr.Medical?

The top shareholders of Indrapr.Medical include the President of India with 26.0%, individual investors with 29.87%, mutual funds at 2.62%, and foreign institutional investors at 2.72%. The largest public shareholder is Quant Mutual Fund's Small Cap Fund, holding 2.61%, while promoters hold the majority of shares with no pledged holdings.

The top shareholders of Indrapr.Medical include the President of India, who holds the largest stake at 26.0%. The company also has a diverse range of shareholders, including individual investors who collectively own 29.87% of the shares. Additionally, mutual funds hold 2.62% of the shares, represented by three different schemes, while foreign institutional investors (FIIs) account for 2.72% through 69 different entities. The highest public shareholder is Quant Mutual Fund, specifically the Quant Small Cap Fund, which holds 2.61%. Overall, the majority of the shares are held by promoters, with no pledged promoter holdings reported.

How big is Indrapr.Medical?

As of 24th July, Indraprastha Medical Corporation Ltd has a market capitalization of 4,382.00 Cr, with recent Net Sales of 1,356.36 Cr and a Net Profit of 160.99 Cr. Shareholder's Funds are 477.76 Cr and Total Assets amount to 723.24 Cr as of March 2024.

As of 24th July, Indraprastha Medical Corporation Ltd has a market capitalization of 4,382.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,356.36 Cr and a Net Profit of 160.99 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 477.76 Cr and Total Assets of 723.24 Cr.

How has been the historical performance of Indrapr.Medical?

Indrapr.Medical has demonstrated consistent growth in net sales and profitability, with net sales increasing from INR 613.38 crore in March 2021 to INR 1,356.36 crore in March 2025, and profit after tax rising from INR 2.33 crore to INR 160.99 crore during the same period. The company's financial performance reflects strong upward momentum in sales, profits, and asset growth.

Answer:<BR>The historical performance of Indrapr.Medical shows a consistent growth trend in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Indrapr.Medical's net sales have increased significantly from INR 613.38 crore in March 2021 to INR 1,356.36 crore in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar upward trend, reaching INR 1,356.36 crore in March 2025, up from INR 888.16 crore in March 2022. Operating profit, excluding other income, also saw a substantial rise, climbing to INR 244.27 crore in March 2025 from INR 40.26 crore in March 2021. Profit before tax surged to INR 216.32 crore in March 2025, compared to just INR 4.29 crore in March 2021, while profit after tax reached INR 160.99 crore, up from INR 2.33 crore in March 2021. The company's earnings per share (EPS) improved significantly, rising to INR 17.56 in March 2025 from INR 0.25 in March 2021. On the balance sheet, total assets increased to INR 851.62 crore in March 2025 from INR 431.95 crore in March 2021, and total liabilities also grew to INR 851.62 crore from INR 448.99 crore in March 2021. Cash flow from operating activities was INR 156 crore in March 2025, although cash flow from investing activities showed a negative trend at -INR 110 crore. Overall, Indrapr.Medical's financial performance indicates a strong upward momentum in sales, profits, and asset growth over the years.

Is Indrapr.Medical technically bullish or bearish?

As of November 21, 2025, the trend is mildly bullish, supported by weekly MACD and KST indicators, despite mixed signals from Dow Theory and a recent price decline.

As of 21 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly MACD and KST indicators, both showing bullish signals, while the monthly KST is mildly bearish. The Bollinger Bands are also indicating a mildly bullish trend on both weekly and monthly time frames. However, the Dow Theory presents a mixed view with a mildly bearish weekly signal contrasted by a bullish monthly signal. The daily moving averages support the mildly bullish stance, although the recent price action shows a decline from the previous close. Overall, the indicators suggest a cautious bullish outlook amid some bearish signals.

Is Indrapr.Medical overvalued or undervalued?

As of November 24, 2025, Indrapr.Medical is considered undervalued with a PE ratio of 26.84 and strong financial metrics, making it an attractive investment compared to peers like Max Healthcare and Apollo Hospitals, despite recent stock performance lagging behind the Sensex.

As of 24 November 2025, Indrapr.Medical's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 26.84, an EV to EBITDA ratio of 16.51, and a PEG ratio of 1.47, which are competitive compared to its peers. <BR><BR>In comparison, Max Healthcare is deemed very expensive with a PE ratio of 79.41, while Apollo Hospitals, which is also attractive, has a PE ratio of 63.22. This suggests that Indrapr.Medical offers a more favorable valuation relative to its industry counterparts. Additionally, the company's impressive ROCE of 94.11% and ROE of 26.54% further reinforce its strong financial performance. Despite recent stock performance lagging behind the Sensex over the past month, the long-term returns of 487.09% over three years and 883.00% over five years highlight the company's growth potential.

Are Indraprastha Medical Corporation Ltd latest results good or bad?

Indraprastha Medical Corporation Ltd's latest results show an 8.92% year-on-year revenue growth, but a 3.89% decline in net profit due to rising employee costs and contracting margins, indicating mixed performance with challenges in profitability. Investors should monitor cost management and margin stability moving forward.

Indraprastha Medical Corporation Ltd's latest results present a mixed picture. On one hand, the company reported a year-on-year revenue growth of 8.92%, with net sales increasing to ₹381.03 crores in Q2 FY26 from ₹349.82 crores in Q2 FY25. This indicates a healthy demand for healthcare services and an expanding patient base.<BR><BR>However, the sequential performance raises concerns. The net profit for Q2 FY26 declined by 3.89% to ₹49.46 crores, breaking a two-quarter streak of profit growth. This decline is attributed to rising employee costs, which surged 13.29% quarter-on-quarter, consuming much of the revenue gain. Additionally, both operating and PAT margins contracted, signaling pressure on profitability despite the top-line growth.<BR><BR>Overall, while the company shows strength in revenue growth and operational efficiency over the longer term, the recent quarterly results highlight challenges in managing costs and maintaining profitability. Investors may need to monitor these trends closely, especially regarding employee costs and margin stability, as they could impact future performance.

Should I buy, sell or hold Indraprastha Medical Corporation Ltd?

Why is Indraprastha Medical Corporation Ltd falling/rising?

As of 31-Mar, Indraprastha Medical Corporation Ltd's stock price is Rs 369.70, down 3.94% and underperforming its sector. The stock has declined 17.43% year-to-date, with reduced institutional investor participation contributing to its bearish trend.

As of 31-Mar, Indraprastha Medical Corporation Ltd's stock price is falling, currently at Rs 369.70, reflecting a change of -15.15 (-3.94%). The stock has underperformed its sector by -2.06% today and has experienced consecutive declines over the last two days, resulting in a total drop of -8.65% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of broader performance, the stock has seen a year-to-date decline of -17.43%, which is worse than the Sensex's decline of -15.57%. Over the past month, the stock has decreased by -5.27%, while the Sensex has fallen by -10.33%. This suggests that the stock's performance is relatively better than the benchmark in the short term, but the overall trend remains negative.<BR><BR>Moreover, there has been a decrease in institutional investor participation, with a reduction of -2.36% in their stake over the previous quarter, which may contribute to the stock's downward pressure. Despite some positive factors, such as a low debt-to-equity ratio and healthy long-term growth in operating profit, the combination of falling investor participation and recent poor performance has led to the stock's decline.

Which are the latest news on Indrapr.Medical?